relacorilant
Small moleculeexperimental
Relacorilant is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome. It is also under development for the treatment of solid tumors and alcoholism. The drug is a nonsteroidal compound and acts as an antagonist of the glucocorticoid receptor. As of December 2017, it is in phase II clinical trials for Cushing's syndrome and phase I/II clinical studies for solid tumors, while the clinical phase for alcoholism is unknown. — Wikipedia
Clinical trial activity
15 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
8
Phase 3
4
Phase 4
0
Earliest trial started Mar 6, 2018 (NCT03457597)
Timeline
Indications
Studied for
- Adrenocortical Carcinoma · Phase 1
- Cushing Syndrome · Phase 3
- Endometrial Neoplasms · Phase 2
- Fallopian Tube Neoplasms · Phase 3
- Hamartoma · Phase 2
- Healthy Volunteers · Phase 1
- Liver Diseases · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 3
- Pancreatic Neoplasms · Phase 3
- Peritoneal Neoplasms · Phase 3
- Prostatic Neoplasms · Phase 2
Mechanism of action
- Glucocorticoid receptorANTAGONIST
Glucocorticoid receptor antagonist
Ph1 trial initiated in Septemebr 2014, no trial ID found.
- Glucocorticoid receptorINHIBITOR
NR3C1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1- Mol. weight
- 586.57 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRelacorilant ↗
- ChEMBLCHEMBL4068611 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07259317 | Phase 2 | Dec 31, 2025 | Corcept Therapeutics |
| NCT06906341 | Phase 2 | Apr 11, 2025 | Corcept Therapeutics |
| NCT05726292 | Phase 2 | Apr 1, 2025 | University of Chicago |
| NCT05257408 | Phase 3 | Jun 29, 2022 | Corcept Therapeutics, Gynecologic Oncology Group |
| NCT05347979 | Phase 1 | May 25, 2022 | Corcept Therapeutics |
| NCT04795479 | Phase 1 | Jan 22, 2021 | Corcept Therapeutics |
| NCT04373265 | Phase 1 | Jun 30, 2020 | Corcept Therapeutics |
| NCT04329949 | Phase 3 | Apr 30, 2020 | Corcept Therapeutics |
| NCT04308590 | Phase 3 | Mar 31, 2020 | Corcept Therapeutics |
| NCT06094725 | Phase 1 | Jan 6, 2020 | Corcept Therapeutics |
| NCT03776812 | Phase 2 | Jan 28, 2019 | Corcept Therapeutics |
| NCT03697109 | Phase 3 | Oct 16, 2018 | Corcept Therapeutics |
| NCT03540836 | Phase 1 | May 24, 2018 | Corcept Therapeutics |
| NCT03512548 | Phase 1 | Apr 10, 2018 | Corcept Therapeutics |
| NCT03457597 | Phase 1 | Mar 6, 2018 | Corcept Therapeutics |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Corcept Therapeutics | For profit | 14 | 14 | 3 | 2018 |
| Gynecologic Oncology Group | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Chicago | Academic/Hospital | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1